Technology ID
E-160-2013-0

Rapid Detection of Multi-Drug-Resistant Mycobacterium tuberculosis Using Real-Time PCR and High-Resolution Melt Analysis

Linked ID
TAB-2611
Inventors
James Posey (CDC)
Jonas Winchell (CDC)
Kelley Cowart (CDC)
Melissa Ramirez (CDC)
Lead Inventors
James Posey (CDC)
Co-Inventors
Jonas Winchell (CDC)
Kelley Cowart (CDC)
Melissa Ramirez (CDC)
Development Status
  • Early-stage
  • In vitro data available
Applications
Diagnostics
Therapeutic Areas
Infectious Disease
ICs
CDC
Commercial Applications
  • Rapid screening of potential multi-drug-resistant M. tuberculosis
  • Kits for diagnosis of M. tuberculosis
  • Public health programs combating emerging drug-resistance in M. tuberculosis; clinics working with at-risk populations
CDC scientists have developed a rapid, sensitive, and specific real-time PCR assay that is capable of detecting the presence of Mycobacterium tuberculosis and determining its resistance profile to antibiotics, such as rifampicin and isoniazid. Currently, there are few assays available that are capable of both detecting M. tuberculosis and determining the bacteria's drug resistance. This assay incorporates multiple fluorescent chemistries, providing a simple and cost-effective method of determining the bacteria's drug resistance. Additionally, this assay may be used to quickly discriminate Mycobacterium tuberculosis complex (MTBC) strains from non-MTBC strains.
Competitive Advantages
  • Robust and inexpensive way to detect dominant M. tuberculosis mutations
  • Rapid results within 5 hours of obtaining DNA
  • More cost-efficient and less complex than culturing and sequencing methods of determining drug-resistant status

Request More Info

Licensing Contact